TSC-101 is a T cell receptor (TCR)-engineered T cell (TCR-T) therapy candidate in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse following allogeneic bone marrow transplantation (hematopoietic cell transplantation or HCT) (the ALLOHA™ trial, NCT05473910). More information about our ongoing clinical trial can be found here.

We are also developing multiplex TCR-T therapy candidates for the treatment of various solid tumors. Our goal is to build and expand the ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. We are currently engaged in preclinical development of in vivo-engineered T cells using the TCRs in our ImmunoBank.

In addition, we are applying our platform to identify unknown targets that cause T cell-driven autoimmune disorders. We have identified a set of indications in which T cells play a key role and are currently identifying targets and developing potential treatment options for these disorders. Initial indications include ankylosing spondylitis, ulcerative colitis, and scleroderma.